Detalhe da pesquisa
1.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Lancet
; 399(10342): 2212-2225, 2022 06 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35691324
2.
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials.
Clin Exp Immunol
; 211(3): 280-287, 2023 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36729167
3.
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
Lancet
; 398(10304): 981-990, 2021 09 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480858
4.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
Lancet
; 397(10282): 1351-1362, 2021 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33798499
5.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Lancet
; 397(10269): 99-111, 2021 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33306989
6.
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
Lancet
; 396(10267): 1979-1993, 2021 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33220855
7.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Lancet
; 397(10277): 881-891, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33617777
8.
Impact of Vaccination on Haemophilus influenzae Type b Carriage in Healthy Children Less Than 5 Years of Age in an Urban Population in Nepal.
J Infect Dis
; 224(12 Suppl 2): S267-S274, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34469554
9.
Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine.
Mol Syst Biol
; 16(11): e9888, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33210468
10.
Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial.
Lancet
; 390(10111): 2472-2480, 2017 Dec 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28965718
11.
Social deprivation and prognosis in Scottish patients with pulmonary arterial hypertension.
Eur Respir J
; 51(2)2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29386345
12.
Evaluation of the Clinical and Microbiological Response to Salmonella Paratyphi A Infection in the First Paratyphoid Human Challenge Model.
Clin Infect Dis
; 64(8): 1066-1073, 2017 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28158395
13.
An outpatient, ambulant-design, controlled human infection model using escalating doses of Salmonella Typhi challenge delivered in sodium bicarbonate solution.
Clin Infect Dis
; 58(9): 1230-40, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24519873
14.
The Impact of Infant Bacille Calmette-Guérin Vaccination on the Immunogenicity of Other Vaccines: A Randomized Exploratory Study.
Pediatr Infect Dis J
; 2024 May 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-38717982
15.
Optimising DTwP-containing vaccine infant immunisation schedules (OptImms) - a protocol for two parallel, open-label, randomised controlled trials.
Trials
; 24(1): 465, 2023 Jul 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37480110
16.
H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study.
Clin Infect Dis
; 54(5): 661-9, 2012 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22267719
17.
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
Nat Commun
; 12(1): 5861, 2021 10 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34615860
18.
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Nat Med
; 27(2): 279-288, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33335322
19.
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.
Nat Med
; 27(2): 270-278, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33335323
20.
Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants.
Open Forum Infect Dis
; 7(5): ofaa143, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32494580